atovaquone/proguanil

DRUG5 trials

Sponsors

Pfizer, Jimma University, Radboud University Medical Center, Merck Sharp & Dohme LLC

Conditions

MalariaMalaria, Falciparum

Phase 1

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

CompletedNCT06294912

Merck Sharp & Dohme LLCMalaria

Start: 2024-04-18End: 2025-01-06Updated: 2025-01-13

Phase 2

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America

CompletedNCT00084227

PfizerMalaria, Falciparum

Start: 2004-07-31End: 2005-07-31Updated: 2011-05-11

Phase 4

Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials

CompletedNCT00451139

Jimma UniversityMalaria

Updated: 2007-03-23

Unknown Phase

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis

CompletedNCT02080026

Radboud University Medical CenterMalaria

Start: 2014-06-30End: 2015-07-31Updated: 2015-08-10

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection

CompletedNCT02098590

Radboud University Medical CenterMalaria

Start: 2014-10-31End: 2015-11-30Updated: 2016-02-23

Related Papers

Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial.

2017-09-1370 citations